Histogen Welcomes Robert Kellar as Vice President of Research and Development
SAN DIEGO, December 20, 2007 - Histogen,
Inc., a regenerative medicine company developing solutions based on the
products of newborn fibroblasts, announced today that Dr. Robert Kellar
has joined the company as Vice President of Research and Development.
Kellar's knowledge in the field of tissue engineering, and experience in
bringing products from concept through to commercial market, will be
vital in enabling Histogen to meet the company's product launch goals in
the coming year.
New regenerative medicine company armed for growth in 2008
SAN DIEGO, December 20, 2007 - Histogen,
Inc., a regenerative medicine company developing solutions based on the
products of newborn fibroblasts, announced today that Dr. Robert Kellar
has joined the company as Vice President of Research and Development.
Kellar's knowledge in the field of tissue engineering, and experience in
bringing products from concept through to commercial market, will be
vital in enabling Histogen to meet the company's product launch goals in
the coming year.
"I am excited to welcome Robert Kellar to our
new, but rapidly growing, Histogen team," said Dr. Gail Naughton, CEO of
Histogen. "With Rob on board, we look forward to reaching great
milestones in 2008, including bringing our first tissue engineering
products to market. Rob's appointment brings our senior management's
total experience in tissue engineering to more than 50 years."
Dr. Kellar joins Histogen from his positions as
co-owner and President of Development Engineering Sciences, a firm based
in Flagstaff, Arizona. Kellar's prior experience in the biomedical
industry includes positions with both W.L. Gore & Associates and
Advanced Tissue Sciences, where he was involved with commercial
worldwide management of research, product development, business,
marketing, and sales. Kellar has authored over 7 papers and is the
inventor on 5 patents and patent applications. Kellar also serves on the
Scientific Advisory Board for Theregen, a cell therapy company
investigating the cardiovascular applications of the cell-based human
tissue patch, Anginera.
"Histogen's technology will afford the
opportunity for a variety of product possibilities," said Dr. Robert
Kellar. "I'm enthusiastic about joining the Histogen team and I look
forward to the role we can play in advancing the field of tissue
engineering and regenerative medicine."
Histogen, launched in 2007, seeks to redefine
regenerative medicine by developing a series of high value products
without the use of embryonic stem cells or animal products. Through
Histogen's proprietary bioreactors that mimic the embryonic environment,
newborn fibroblasts are encouraged to naturally produce the vital
proteins and growth factors from which the company has developed its
rich product portfolio. Histogen's business plan benefits from the
lessons learned at Advanced Tissue Sciences, and focuses on near, mid
and long term products that are either self-pay or reimbursable.
